In SELECT, semaglutide showed a 20% reduction in major adverse cardiovascular events (MACE) – including cardiovascular death, ...

The total headcount at the group was a little over 99,700 at the end of last year and fell to around 98,200 by the end of ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it ...

Last year, MSD revealed that the co-formulation – given either alone or in combination with docetaxel chemotherapy – also ...

Similarly, the COVID-19 pandemic demonstrated how technology can enable clinical trial efficiencies, such as telemedicine, ...

Along with ACI-24.060, it is also developing a tau protein-targeting immunotherapy for Alzheimer’s (ACI-35.030) with Johnson ...

The first person to receive a transplant of a kidney from a pig has died almost two months after the procedure, although the ...

Monitoring of heart failure patients in their homes using a wearable developed by Analog Devices Inc (ADI) has shown in a new ...

Sanofi will invest more than €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France ...

Three years after turning it down for being too expensive, NICE has backed the use of Pfizer’s Vyndaqel as a treatment for ...

The fear for shareholders is that a delay could mean that mRNA-1345 won’t be ready to roll out in the US in time for the ...

Leela Barham looks at the speediness of NICE’s technology appraisals and ongoing efforts to hit the target of NICE publishing ...